Pfizer and UCB Announce Formation of New Company 'Cyclofluidic' to Accelerate Drug Discovery Process
News Nov 17, 2008
Pfizer Ltd and UCB announced the formation of Cyclofluidic, a technology company established with the aim of significantly accelerating the drug discovery process by allowing researchers to test a greater range of potential new medicines in a shorter time.
The UK Government's Technology Strategy Board has helped facilitate this arrangement between Pfizer and UCB and will continue to support Cyclofluidic by co-funding its R&D.
The aim of Cyclofluidic is to develop technologies that automate and integrate processes known as flow chemistry and flow biology to help pharmaceutical companies shorten timelines within the drug development process.
"Cyclofluidic's entry into the rapidly evolving microfluidic technology area has the potential to radically transform the medicinal chemistry and biology interface." Says Dr Neil Weir, Senior Vice President Research at UCB. "It's an exciting opportunity for UCB and Pfizer to collaborate and offers real potential for improved productivity, underlining our commitment to innovation for patients."
Peter Luke, Senior Director, Worldwide Business Development at Pfizer said, "This is a great example of how public-private partnerships can provide innovative technologies to speed medicines to market. We are impressed by the way the Technology Strategy Board has initiated a novel and creative deal structure."
Cyclofluidic will be jointly owned by Pfizer and UCB, with each company having both a seat and scientific observer rights on the board.
Currently, it takes between 12-15 years and a cost of up to £500 million to develop a new medicine. One of the most time-intensive and skilful parts of pharmaceutical research is the screening of potential medicines against therapeutic targets.
Cyclofluidic will develop a microfluidic closed loop lead optimization platform which will enable researchers to access state of the art expertise in flow chemistry, flow screening and microfluidic engineering. This will be addressed through extensive collaboration with key academics and component manufacturers
Cyclofluidic will also provide training for both flow chemistry and biology scientists at its facility, to be located in the South of England.
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018